drugset / Trial / NCT02134366
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
RandomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
Timeline
- Start
- 2014-07
- Primary completion
- 2017-07
- Completion
- 2017-07
Outcome
Outcome not reported
Stopped (Enrollment): “Recruitment Issues - Lack of target population”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clobazam | Small molecule | 5 mg | — |
| Subject | Clobazam | Small molecule | 25 mg | — |
| Subject | Clonazepam | Small molecule | 1 mg | — |
| Subject | Clonazepam | Small molecule | 2 mg | — |
| Subject | Lorazepam | Small molecule | 1 mg | — |
| Subject | Lorazepam | Small molecule | 2 mg | — |